Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F24%3A10158773" target="_blank" >RIV/00098892:_____/24:10158773 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/10.1002/hem3.70004" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/hem3.70004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hem3.70004" target="_blank" >10.1002/hem3.70004</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Popis výsledku v původním jazyce

The introduction of novel small molecule inhibitors has transformed the management of chronic lymphocytic leukemia (CLL), demonstrating superiority over traditional chemoimmunotherapy (CIT) in various settings. This retrospective study by the European Research Initiative on CLL (ERIC) analyzed real-world treatment patterns and outcomes among 7,382 patients diagnosed with CLL or small lymphocytic lymphoma (SLL) from 2000 to 2016 across 76 centers in 25 countries. The median age at diagnosis was 64 years, with most patients (93.2%) receiving at least one line of chemotherapy or CIT. The most prevalent first-line regimen was FCR (35.3%), particularly among younger patients. While BTK inhibitors (BTKis) were used in only 2% of patients as frontline treatment, they were the most common therapy for relapsed/refractory (R/R) cases. Notably, the study found that chemotherapy and CIT usage decreased after 2014, with significant variations in treatment choices for R/R patients. Discontinuation due to toxicity was a concern, especially among patients treated with PI3K inhibitors, while venetoclax showed a lower discontinuation rate. The study highlighted the delayed adoption of novel agents, even after their proven efficacy, raising questions about treatment accessibility and physician decision-making. Despite limitations, the findings underscore the need for improved integration of novel therapies into clinical practice and a better understanding of the barriers to their use.

Název v anglickém jazyce

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

Popis výsledku anglicky

The introduction of novel small molecule inhibitors has transformed the management of chronic lymphocytic leukemia (CLL), demonstrating superiority over traditional chemoimmunotherapy (CIT) in various settings. This retrospective study by the European Research Initiative on CLL (ERIC) analyzed real-world treatment patterns and outcomes among 7,382 patients diagnosed with CLL or small lymphocytic lymphoma (SLL) from 2000 to 2016 across 76 centers in 25 countries. The median age at diagnosis was 64 years, with most patients (93.2%) receiving at least one line of chemotherapy or CIT. The most prevalent first-line regimen was FCR (35.3%), particularly among younger patients. While BTK inhibitors (BTKis) were used in only 2% of patients as frontline treatment, they were the most common therapy for relapsed/refractory (R/R) cases. Notably, the study found that chemotherapy and CIT usage decreased after 2014, with significant variations in treatment choices for R/R patients. Discontinuation due to toxicity was a concern, especially among patients treated with PI3K inhibitors, while venetoclax showed a lower discontinuation rate. The study highlighted the delayed adoption of novel agents, even after their proven efficacy, raising questions about treatment accessibility and physician decision-making. Despite limitations, the findings underscore the need for improved integration of novel therapies into clinical practice and a better understanding of the barriers to their use.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

HemaSphere

ISSN

—

e-ISSN

2572-9241

Svazek periodika

8

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

"e70004"

Kód UT WoS článku

001314048700001

EID výsledku v databázi Scopus

2-s2.0-85204215391